Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 42

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Fluoroquinolones and Biofilm: A Narrative Review

Geremia, Nicholas, Giovagnorio, Federico, Colpani, Agnese, De Vito, Andrea, Botan, Alexandru, Stroffolini, Giacomo, Toc, Dan-Alexandru, Zerbato, Verena, Principe, Luigi, Madeddu, Giordano, Luzzati, Roberto, Parisi, Saverio Giuseppe, Di Bella, Stefano · 2024 · Pharmaceuticals

Abstract

Background: Biofilm-associated infections frequently span multiple body sites and represent a significant clinical challenge, often requiring a multidisciplinary approach involving surgery and antimicrobial therapy. These infections are commonly healthcare-associated and frequently related to internal or external medical devices. The formation of biofilms complicates treatment, as they create environments that are difficult for most antimicrobial agents to penetrate. Fluoroquinolones play a critical role in the eradication of biofilm-related infections. Numerous studies have investigated the synergistic potential of combining fluoroquinolones with other chemical agents to augment their efficacy while minimizing potential toxicity. Comparative research suggests that the antibiofilm activity of fluoroquinolones is superior to that of beta-lactams and glycopeptides. However, their activity remains less effective than that of minocycline and fosfomycin. Noteworthy combinations include fluoroquinolones with fosfomycin and aminoglycosides for enhanced activity against Gram-negative organisms and fluoroquinolones with minocycline and rifampin for more effective treatment of Gram-positive infections. Despite the limitations of fluoroquinolones due to the intrinsic characteristics of this antibiotic, they remain fundamental in this setting thanks to their bioavailability and synergisms with other drugs. Methods: A comprehensive literature search was conducted using online databases (PubMed/MEDLINE/Google Scholar) and books written by experts in microbiology and infectious diseases to identify relevant studies on fluoroquinolones and biofilm. Results: This review critically assesses the role of fluoroquinolones in managing biofilm-associated infections in various clinical settings while also exploring the potential benefits of combination therapy with these antibiotics. Conclusions: The literature predominantly consists of in vitro studies, with limited in vivo investigations. Although real world data are scarce, they are in accordance with fluoroquinolones’ effectiveness in managing early biofilm-associated infections. Also, future perspectives of newer treatment options to be placed alongside fluoroquinolones are discussed. This review underscores the role of fluoroquinolones in the setting of biofilm-associated infections, providing a comprehensive guide for physicians regarding the best use of this class of antibiotics while highlighting the existing critical issues.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ph17121673

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 233

  1. Tdm, 2019, Quinolone Antibiotics, MedChemComm, 10, 1719, 10.1039/C9MD00120D · DOI · Paper page
  2. Adjei, 2007, Identification of Metabolites Produced from N-Phenylpiperazine by Mycobacterium Spp., J. Ind. Microbiol. Biotechnol., 34, 219, 10.1007/s10295-006-0189-x · doi:10.1007/s10295-006-0189-x
  3. Andersson, 2003, Development of the Quinolones, J. Antimicrob. Chemother., 51, 1, 10.1093/jac/dkg212 · DOI
  4. Marrie, 1982, A Scanning and Transmission Electron Microscopic Study of an Infected Endocardial Pacemaker Lead, Circulation, 66, 1339, 10.1161/01.CIR.66.6.1339 · DOI · Paper page
  5. 2018, Biofilm-Related Disease, Expert Rev. Anti Infect. Ther., 16, 51, 10.1080/14787210.2018.1417036 · DOI · Paper page
  6. Rottier, 2023, Antimicrobial Treatment of Patients with a Periprosthetic Joint Infection: Basic Principles, Arthroplasty, 5, 10, 10.1186/s42836-023-00169-4 · DOI
  7. Willmott, 1993, A Single Point Mutation in the DNA Gyrase A Protein Greatly Reduces Binding of Fluoroquinolones to the Gyrase-DNA Complex, Antimicrob. Agents Chemother., 37, 126, 10.1128/AAC.37.1.126 · DOI · Paper page
  8. Brar, 2020, Fluoroquinolone Antibiotics: An Overview, Adesh Univ. J. Med. Sci. Res., 2, 26
  9. Bhatt, 2022, Fluoroquinolone Antibiotics: Occurrence, Mode of Action, Resistance, Environmental Detection, and Remediation—A Comprehensive Review, Environ. Pollut., 315, 120440, 10.1016/j.envpol.2022.120440 · DOI · Paper page
  10. Jia, 2021, The Antibacterial Activity of Fluoroquinolone Derivatives: An Update (2018-2021), Eur. J. Med. Chem., 224, 113741, 10.1016/j.ejmech.2021.113741 · doi:10.1016/j.ejmech.2021.113741
  11. Dewulf, 2014, Fluoroquinolone Antibiotics: An Emerging Class of Environmental Micropollutants, Sci. Total Environ., 500–501, 250
  12. Kabbani, 2018, Opportunities to Improve Fluoroquinolone Prescribing in the United States for Adult Ambulatory Care Visits, Clin. Infect. Dis., 67, 134, 10.1093/cid/ciy035 · DOI
  13. Gelone, 2000, Fluoroquinolones, Infect. Dis. Clin. N. Am., 14, 489, 10.1016/S0891-5520(05)70260-9 · DOI
  14. Werner, N.L., Hecker, M.T., Sethi, A.K., and Donskey, C.J. (2011). Unnecessary Use of Fluoroquinolone Antibiotics in Hospitalized Patients. BMC Infect. Dis., 11. · DOI
  15. Correia, 2017, Mechanisms of Quinolone Action and Resistance: Where Do We Stand?, J. Med. Microbiol., 66, 551, 10.1099/jmm.0.000475 · DOI · Paper page
  16. Kohanski, 2010, How Antibiotics Kill Bacteria: From Targets to Networks, Nat. Rev. Microbiol., 8, 423, 10.1038/nrmicro2333 · DOI · Paper page
  17. Blondeau, 2004, Fluoroquinolones: Mechanism of Action, Classification, and Development of Resistance, Surv. Ophthalmol., 49, S73, 10.1016/j.survophthal.2004.01.005 · doi:10.1016/j.survophthal.2004.01.005
  18. Qu, 2021, Characterization of Lactobacillus Reuteri WQ-Y1 with the Ciprofloxacin Degradation Ability, Biotechnol. Lett., 43, 855, 10.1007/s10529-020-03068-9 · DOI
  19. Dube, 2023, Quinolone: A Versatile Therapeutic Compound Class, Mol. Divers., 27, 1501, 10.1007/s11030-022-10581-8 · DOI
  20. Zahari, N.I.N., Engku Abd Rahman, E.N.S., Irekeola, A.A., Ahmed, N., Rabaan, A.A., Alotaibi, J., Alqahtani, S.A., Halawi, M.Y., Alamri, I.A., and Almogbel, M.S. (2023). A Review of the Resistance Mechanisms for β-Lactams, Macrolides and Fluoroquinolones among Streptococcus Pneumoniae. Med. Kaunas Lith., 59. · DOI
  21. Xu, 2017, Moxifloxacin Is an Effective and Safe Candidate Agent for Tuberculosis Treatment: A Meta-Analysis, Int. J. Infect. Dis., 60, 35, 10.1016/j.ijid.2017.05.003 · doi:10.1016/j.ijid.2017.05.003
  22. Gillespie, 2016, The Role of Moxifloxacin in Tuberculosis Therapy, Eur. Respir. Rev., 25, 19, 10.1183/16000617.0085-2015 · DOI
  23. Saravolatz, 2019, Delafloxacin: A New Anti-Methicillin-Resistant Staphylococcus Aureus Fluoroquinolone, Clin. Infect. Dis., 68, 1058, 10.1093/cid/ciy600 · DOI
  24. Lee, 2022, Delafloxacin: A Review in Community-Acquired Pneumonia, Drugs, 82, 913, 10.1007/s40265-022-01725-z · DOI
  25. Morales, 2018, Indications for Systemic Fluoroquinolone Therapy in Europe and Prevalence of Primary-Care Prescribing in France, Germany and the UK: Descriptive Population-Based Study, Clin. Drug Investig., 38, 927, 10.1007/s40261-018-0684-7 · doi:10.1007/s40261-018-0684-7
  26. Kelly, 2021, Fluoroquinolone Use in a Rural Practice, Can. J. Rural. Med., 26, 14, 10.4103/cjrm.cjrm_67_20 · doi:10.4103/cjrm.cjrm_67_20
  27. Aminimanizani, 2001, Comparative Pharmacokinetics and Pharmacodynamics of the Newer Fluoroquinolone Antibacterials, Clin. Pharmacokinet., 40, 169, 10.2165/00003088-200140030-00003 · doi:10.2165/00003088-200140030-00003
  28. Sharma, 2009, Fluoroquinolone Antibacterials: A Review on Chemistry, Microbiology and Therapeutic Prospects, Acta Pol. Pharm., 66, 587
  29. Tulkens, 2009, Safety Profile of the Respiratory Fluoroquinolone Moxifloxacin: Comparison with Other Fluoroquinolones and Other Antibacterial Classes, Drug Saf., 32, 359, 10.2165/00002018-200932050-00001 · DOI
  30. Tam, 2014, Fluoroquinolone-Induced Achilles Tendinitis, Hong Kong Med. J. Xianggang Yi Xue Za Zhi, 20, 545, 10.12809/hkmj134105 · doi:10.12809/hkmj134105
  31. Annisa, N., Barliana, M.I., Santoso, P., and Ruslami, R. (2022). Transporter and Metabolizer Gene Polymorphisms Affect Fluoroquinolone Pharmacokinetic Parameters. Front. Pharmacol., 13. · DOI
  32. Jamal, 2018, Bacterial Biofilm and Associated Infections, J. Chin. Med. Assoc., 81, 7, 10.1016/j.jcma.2017.07.012 · DOI · Paper page
  33. Stewart, 2014, Biophysics of Biofilm Infection, Pathog. Dis., 70, 212, 10.1111/2049-632X.12118 · DOI
  34. 2015, Biofilm Development, Microbiol. Spectr., 3, 51
  35. 2002, Understanding Bacterial Biofilms in Patients with Cystic Fibrosis: Current and Innovative Approaches to Potential Therapies, J. Cyst. Fibros., 1, 249, 10.1016/S1569-1993(02)00104-2 · DOI
  36. Niveditha, 2012, The Isolation and the Biofilm Formation of Uropathogens in the Patients with Catheter Associated Urinary Tract Infections (UTIs), J. Clin. Diagn. Res. JCDR, 6, 1478
  37. Hemmati, 2021, Novel Strategies to Combat Bacterial Biofilms, Mol. Biotechnol., 63, 569, 10.1007/s12033-021-00325-8 · DOI
  38. Meneses, 2023, A Systematic Review of the Use of Bacteriophages for in Vitro Biofilm Control, Eur. J. Clin. Microbiol. Infect. Dis., 42, 919, 10.1007/s10096-023-04638-1 · DOI
  39. Zimmerli, 2004, Prosthetic-Joint Infections, N. Engl. J. Med., 351, 1645, 10.1056/NEJMra040181 · DOI · Paper page
  40. Conen, 2020, Management of Neurosurgical Implant-Associated Infections, Swiss Med. Wkly., 150, w20208
  41. Olson, 2002, Biofilm Bacteria: Formation and Comparative Susceptibility to Antibiotics, Can. J. Vet. Res. Rev. Can. Rech. Veterinaire, 66, 86
  42. Hathroubi, 2018, Helicobacter Pylori Biofilm Formation and Its Potential Role in Pathogenesis, Microbiol. Mol. Biol. Rev. MMBR, 82, e00001-18, 10.1128/MMBR.00001-18 · DOI · Paper page
  43. Przekwas, J., Gębalski, J., Kwiecińska-Piróg, J., Wiktorczyk-Kapischke, N., Wałecka-Zacharska, E., Gospodarek-Komkowska, E., Rutkowska, D., and Skowron, K. (2022). The Effect of Fluoroquinolones and Antioxidans on Biofilm Formation by Proteus Mirabilis Strains. Ann. Clin. Microbiol. Antimicrob., 21. · DOI
  44. Masadeh, M.M., Alzoubi, K.H., Ahmed, W.S., and Magaji, A.S. (2019). In Vitro Comparison of Antibacterial and Antibiofilm Activities of Selected Fluoroquinolones against Pseudomonas Aeruginosa and Methicillin-Resistant Staphylococcus Aureus. Pathogens, 8. · DOI
  45. Balsalobre, 2012, Biofilm Infections, Their Resilience to Therapy and Innovative Treatment Strategies, J. Intern. Med., 272, 541, 10.1111/joim.12004 · DOI · Paper page
  46. Tunkel, 2017, 2017 Infectious Diseases Society of America’s Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis, Clin. Infect. Dis., 64, e34, 10.1093/cid/ciw861 · DOI · Paper page
  47. Darouiche, 2004, Treatment of Infections Associated with Surgical Implants, N. Engl. J. Med., 350, 1422, 10.1056/NEJMra035415 · DOI · Paper page
  48. Colombo, 2022, Treatment with Cefiderocol in K. Pneumoniae KPC Nosocomial External Ventricular Drainage Meningitis: A Brief Report, Infez. Med., 30, 454
  49. Motta, 2014, Analysis of Complications in 430 Consecutive Pediatric Patients Treated with Intrathecal Baclofen Therapy: 14-Year Experience, J. Neurosurg. Pediatr., 13, 301, 10.3171/2013.11.PEDS13253 · doi:10.3171/2013.11.peds13253
  50. Soriano, 2013, Assessment of the in Vivo Formation of Biofilm on External Ventricular Drainages, Eur. J. Clin. Microbiol. Infect. Dis., 32, 1437, 10.1007/s10096-013-1895-8 · doi:10.1007/s10096-013-1895-8
  51. Destache, 2001, Cerebrospinal Fluid Penetration and Pharmacokinetics of Levofloxacin in an Experimental Rabbit Meningitis Model, J. Antimicrob. Chemother., 47, 611, 10.1093/jac/47.5.611 · doi:10.1093/jac/47.5.611
  52. Lutsar, 1998, Antibiotic Pharmacodynamics in Cerebrospinal Fluid, Clin. Infect. Dis., 27, 1117, 10.1086/515003 · DOI · Paper page
  53. Nau, 2010, Penetration of Drugs through the Blood-Cerebrospinal Fluid/Blood-Brain Barrier for Treatment of Central Nervous System Infections, Clin. Microbiol. Rev., 23, 858, 10.1128/CMR.00007-10 · DOI · Paper page
  54. Shariati, A., Arshadi, M., Khosrojerdi, M.A., Abedinzadeh, M., Ganjalishahi, M., Maleki, A., Heidary, M., and Khoshnood, S. (2022). The Resistance Mechanisms of Bacteria against Ciprofloxacin and New Approaches for Enhancing the Efficacy of This Antibiotic. Front. Public Health, 10. · DOI · Paper page
  55. Karvouniaris, 2022, Current Perspectives on the Diagnosis and Management of Healthcare-Associated Ventriculitis and Meningitis, Infect. Drug Resist., 15, 697, 10.2147/IDR.S326456 · DOI
  56. Verderosa, 2017, Ciprofloxacin-Nitroxide Hybrids with Potential for Biofilm Control, Eur. J. Med. Chem., 138, 590, 10.1016/j.ejmech.2017.06.058 · DOI
  57. Voinescu, 2024, A Comprehensive Review of Microbial Biofilms on Contact Lenses: Challenges and Solutions, Infect. Drug Resist., 17, 2659, 10.2147/IDR.S463779 · doi:10.2147/idr.s463779
  58. Borroni, D., Paytuví-Gallart, A., Sanseverino, W., Gómez-Huertas, C., Bonci, P., Romano, V., Giannaccare, G., Rechichi, M., Meduri, A., and Oliverio, G.W. (2022). Exploring the Healthy Eye Microbiota Niche in a Multicenter Study. Int. J. Mol. Sci., 23. · doi:10.3390/ijms231810229
  59. Borroni, 2023, Ocular Microbiome Evaluation in Dry Eye Disease and Meibomian Gland Dysfunction: Values of Variables, Exp. Eye Res., 236, 109656, 10.1016/j.exer.2023.109656 · doi:10.1016/j.exer.2023.109656
  60. Borrone, 2024, The Influence of Lid-Parallel Conjunctival Folds and Conjunctivochalasis on Dry Eye Symptoms with and Without Contact Lens Wear: A Review of the Literature, Ophthalmol. Ther., 13, 651, 10.1007/s40123-023-00877-9 · doi:10.1007/s40123-023-00877-9
  61. Chhabra, 2006, Endophthalmitis after Open Globe Injury: Microbiologic Spectrum and Susceptibilities of Isolates, Am. J. Ophthalmol., 142, 852, 10.1016/j.ajo.2006.05.024 · doi:10.1016/j.ajo.2006.05.024
  62. Pachigolla, 2007, Microbial Keratitis Pathogens and Antibiotic Susceptibilities: A 5-Year Review of Cases at an Urban County Hospital in North Texas, Eye Contact Lens, 33, 45, 10.1097/01.icl.0000234002.88643.d0 · doi:10.1097/01.icl.0000234002.88643.d0
  63. Willcox, 2023, Biofilms and Contact Lenses: Problems and Solutions, Microbiol. Aust., 44, 96, 10.1071/MA23027 · doi:10.1071/ma23027
  64. Donlan, 2001, Biofilms and Device-Associated Infections, Emerg. Infect. Dis., 7, 277, 10.3201/eid0702.010226 · DOI · Paper page
  65. Lodha, 2022, Biofilm Formation and Its Effect on the Management of Culture-Positive Bacterial Endophthalmitis, Indian J. Ophthalmol., 70, 472, 10.4103/ijo.IJO_1872_21 · doi:10.4103/ijo.ijo_1872_21
  66. Wozniak, 2017, Antibiotics in Ophthalmology Practice, Expert Rev. Ophthalmol., 12, 243, 10.1080/17469899.2017.1318065 · doi:10.1080/17469899.2017.1318065
  67. Marone, 2010, Ocular Infections: Antibiotics and Bacterial Adhesion on Biomaterials Used in Ocular Surgery, Ophthalmologica, 209, 315, 10.1159/000310649 · doi:10.1159/000310649
  68. Gentili, 2024, Comparison Between Moxifloxacin and Chloramphenicol for the Treatment of Bacterial Eye Infections, Curr. Ther. Res., 100, 100740, 10.1016/j.curtheres.2024.100740 · doi:10.1016/j.curtheres.2024.100740
  69. Diriba, K., Kassa, T., Alemu, Y., and Bekele, S. (2020). In Vitro Biofilm Formation and Antibiotic Susceptibility Patterns of Bacteria from Suspected External Eye Infected Patients Attending Ophthalmology Clinic, Southwest Ethiopia. Int. J. Microbiol., 2020. · doi:10.1155/2020/8472395
  70. Thirumalmuthu, 2019, Mechanisms of Fluoroquinolone and Aminoglycoside Resistance in Keratitis-Associated Pseudomonas Aeruginosa, Microb. Drug Resist. Larchmt. N, 25, 813, 10.1089/mdr.2018.0218 · DOI
  71. Garty, 2011, Sustained Antibiotic Release from an Intraocular Lens-Hydrogel Assembly for Cataract Surgery, Investig. Ophthalmol. Vis. Sci., 52, 6109, 10.1167/iovs.10-6071 · DOI
  72. Schilder, 2016, Otitis Media, Nat. Rev. Dis. Primer, 2, 16063, 10.1038/nrdp.2016.63 · DOI · Paper page
  73. Harmes, 2013, Otitis Media: Diagnosis and Treatment, Am. Fam. Physician, 88, 435
  74. Coker, 2010, Diagnosis, Microbial Epidemiology, and Antibiotic Treatment of Acute Otitis Media in Children: A Systematic Review, JAMA, 304, 2161, 10.1001/jama.2010.1651 · DOI · Paper page
  75. Jacobs, 1998, Prevalence of Antimicrobial-Resistant Pathogens in Middle Ear Fluid: Multinational Study of 917 Children with Acute Otitis Media, Antimicrob. Agents Chemother., 42, 589, 10.1128/AAC.42.3.589 · DOI · Paper page
  76. Ngo, C.C., Massa, H.M., Thornton, R.B., and Cripps, A.W. (2016). Predominant Bacteria Detected from the Middle Ear Fluid of Children Experiencing Otitis Media: A Systematic Review. PLoS ONE, 11. · DOI · Paper page
  77. Lampikoski, 2012, Mastoid Biofilm in Chronic Otitis Media, Otol. Neurotol. Off. Publ. Am. Otol. Soc. Am. Neurotol. Soc. Eur. Acad. Otol. Neurotol., 33, 785, 10.1097/MAO.0b013e318259533f · doi:10.1097/mao.0b013e318259533f
  78. Gu, 2014, Detection of Bacterial Biofilms in Different Types of Chronic Otitis Media, Eur. Arch. Oto-Rhino-Laryngol., 271, 2877, 10.1007/s00405-013-2766-8 · DOI
  79. Lambert, 2016, Haemophilus Influenzae Biofilm Formation in Chronic Otitis Media with Effusion, Eur. Arch. Oto-Rhino-Laryngol., 273, 3553, 10.1007/s00405-016-3958-9 · DOI
  80. Mittal, 2015, Current Concepts in the Pathogenesis and Treatment of Chronic Suppurative Otitis Media, J. Med. Microbiol., 64, 1103, 10.1099/jmm.0.000155 · DOI · Paper page
  81. Grubb, 2010, Treatment Failure, Recurrence, and Antibiotic Prescription Rates for Different Acute Otitis Media Treatment Methods, Clin. Pediatr. (Phila.), 49, 970, 10.1177/0009922810370363 · doi:10.1177/0009922810370363
  82. Moriyama, 2009, Formation of Biofilm by Haemophilus Influenzae Isolated from Pediatric Intractable Otitis Media, Auris. Nasus. Larynx, 36, 525, 10.1016/j.anl.2008.10.010 · DOI
  83. Takei, 2013, Minimal Biofilm Eradication Concentration of Antimicrobial Agents against Nontypeable Haemophilus Influenzae Isolated from Middle Ear Fluids of Intractable Acute Otitis Media, J. Infect. Chemother., 19, 504, 10.1007/s10156-013-0592-y · DOI
  84. Kaji, 2008, Antimicrobial Effect of Fluoroquinolones for the Eradication of Nontypeable Haemophilus Influenzae Isolates within Biofilms, Tohoku J. Exp. Med., 214, 121, 10.1620/tjem.214.121 · DOI
  85. Novotny, 2021, Humanized Anti-DNABII Fab Fragments Plus Ofloxacin Eradicated Biofilms in Experimental Otitis Media, Laryngoscope, 131, E2698, 10.1002/lary.29497 · DOI
  86. Khomtchouk, K.M., Joseph, L.I., Khomtchouk, B.B., Kouhi, A., Massa, S., Xia, A., Koliesnik, I., Pletzer, D., Bollyky, P.L., and Santa Maria, P.L. (2021). Treatment with a Neutrophil Elastase Inhibitor and Ofloxacin Reduces P. Aeruginosa Burden in a Mouse Model of Chronic Suppurative Otitis Media. NPJ Biofilms Microbiomes, 7. · DOI
  87. Senneville, E., Gachet, B., Blondiaux, N., and Robineau, O. (2023). Do Anti-Biofilm Antibiotics Have a Place in the Treatment of Diabetic Foot Osteomyelitis?. Antibiotics, 12. · doi:10.20944/preprints202301.0333.v1
  88. Almasri, D., and Dahman, Y. (2023). Prosthetic Joint Infections: Biofilm Formation, Management, and the Potential of Mesoporous Bioactive Glass as a New Treatment Option. Pharmaceutics, 15. · doi:10.3390/pharmaceutics15051401
  89. Trampuz, 2007, Sonication of Removed Hip and Knee Prostheses for Diagnosis of Infection, N. Engl. J. Med., 357, 654, 10.1056/NEJMoa061588 · DOI · Paper page
  90. Ramage, 2003, Formation of Propionibacterium Acnes Biofilms on Orthopaedic Biomaterials and Their Susceptibility to Antimicrobials, Biomaterials, 24, 3221, 10.1016/S0142-9612(03)00173-X · DOI · Paper page
  91. Bjarnsholt, 2015, ESCMID Guideline for the Diagnosis and Treatment of Biofilm Infections 2014, Clin. Microbiol. Infect., 21, S1, 10.1016/j.cmi.2014.10.024 · DOI · Paper page
  92. Høiby, N., Moser, C., Oliver, A., Williams, C., Ramage, G., Borghi, E., Azeredo, J., Macia, M.D., and European Society for Clinical Microbiology and Infectious Disease Study Group for Biofilms (ESGB) (2023). To Update or Not to Update the ESCMID Guidelines for the Diagnosis and Treatment of Biofilm Infections—That Is the Question! The Opinion of the ESGB Board. Biofilm, 6. · DOI
  93. Wang, L., Di Luca, M., Tkhilaishvili, T., Trampuz, A., and Gonzalez Moreno, M. (2019). Synergistic Activity of Fosfomycin, Ciprofloxacin, and Gentamicin Against Escherichia Coli and Pseudomonas Aeruginosa Biofilms. Front. Microbiol., 10. · DOI
  94. Widmer, 1991, Killing of Nongrowing and Adherent Escherichia Coli Determines Drug Efficacy in Device-Related Infections, Antimicrob. Agents Chemother., 35, 741, 10.1128/AAC.35.4.741 · DOI
  95. Holmberg, 2012, Effectiveness of Ciprofloxacin or Linezolid in Combination with Rifampicin against Enterococcus Faecalis in Biofilms, J. Antimicrob. Chemother., 67, 433, 10.1093/jac/dkr477 · doi:10.1093/jac/dkr477
  96. Fily, 2019, Moxifloxacin-Rifampicin Combination for the Treatment of Non-Staphylococcal Gram-Positive Orthopedic Implant-Related Infections, Med. Mal. Infect., 49, 540, 10.1016/j.medmal.2019.06.008 · doi:10.1016/j.medmal.2019.06.008
  97. Perez-Alba, E., Flores-Treviño, S., Villarreal-Salazar, V., Bocanegra-Ibarias, P., Vilchez-Cavazos, F., and Camacho-Ortiz, A. (2023). Planktonic and Biofilm States of Staphylococcus Aureus Isolated from Bone and Joint Infections and the in Vitro Effect of Orally Available Antibiotics. J. Appl. Microbiol., 134. · DOI
  98. Greimel, 2017, Efficacy of Antibiotic Treatment of Implant-Associated Staphylococcus Aureus Infections with Moxifloxacin, Flucloxacillin, Rifampin, and Combination Therapy: An Animal Study, Drug Des. Devel. Ther., 11, 1729, 10.2147/DDDT.S138888 · DOI
  99. Kalteis, 2006, Treatment of Implant-Associated Infections with Moxifloxacin: An Animal Study, Int. J. Antimicrob. Agents, 27, 444, 10.1016/j.ijantimicag.2005.12.003 · doi:10.1016/j.ijantimicag.2005.12.003
  100. Munaweera, 2018, Temperature-Sensitive Liposomal Ciprofloxacin for the Treatment of Biofilm on Infected Metal Implants Using Alternating Magnetic Fields, Int. J. Hyperth., 34, 189, 10.1080/02656736.2017.1422028 · DOI
  101. Habib, 1999, Preparation and Characterization of Ofloxacin Microspheres for the Eradication of Bone Associated Bacterial Biofilm, J. Microencapsul., 16, 27, 10.1080/026520499289284 · doi:10.1080/026520499289284
  102. Ferreira, 2017, Levofloxacin-Loaded Bone Cement Delivery System: Highly Effective against Intracellular Bacteria and Staphylococcus Aureus Biofilms, Int. J. Pharm., 532, 241, 10.1016/j.ijpharm.2017.08.089 · DOI
  103. Matos, 2015, Key-Properties Outlook of a Levofloxacin-Loaded Acrylic Bone Cement with Improved Antibiotic Delivery, Int. J. Pharm., 485, 317, 10.1016/j.ijpharm.2015.03.035 · DOI
  104. Sedghizadeh, P.P., Cherian, P., Roshandel, S., Tjokro, N., Chen, C., Junka, A.F., Hu, E., Neighbors, J., Pawlak, J., and Russell, R.G.G. (2023). Real-Time Impedance-Based Monitoring of the Growth and Inhibition of Osteomyelitis Biofilm Pathogen Staphylococcus Aureus Treated with Novel Bisphosphonate-Fluoroquinolone Antimicrobial Conjugates. Int. J. Mol. Sci., 24. · doi:10.3390/ijms24031985
  105. Sedghizadeh, 2017, Design, Synthesis, and Antimicrobial Evaluation of a Novel Bone-Targeting Bisphosphonate-Ciprofloxacin Conjugate for the Treatment of Osteomyelitis Biofilms, J. Med. Chem., 60, 2326, 10.1021/acs.jmedchem.6b01615 · DOI
  106. Memar, M.Y., Ahangarzadeh Rezaee, M., Barzegar-Jalali, M., Gholikhani, T., and Adibkia, K. (2023). The Antibacterial Effect of Ciprofloxacin Loaded Calcium Carbonate (CaCO3) Nanoparticles Against the Common Bacterial Agents of Osteomyelitis. Curr. Microbiol., 80. · DOI
  107. Wilson, 2016, Vascular Graft Infections, Mycotic Aneurysms, and Endovascular Infections: A Scientific Statement From the American Heart Association, Circulation, 134, e412, 10.1161/CIR.0000000000000457 · DOI · Paper page
  108. Chiesa, 2002, Vascular Prosthetic Graft Infection: Epidemiology, Bacteriology, Pathogenesis and Treatment, Acta Chir. Belg., 102, 238, 10.1080/00015458.2002.11679305 · DOI
  109. Antonios, 2006, Prosthetic Vascular Graft Infection: A Risk Factor Analysis Using a Case-Control Study, J. Infect., 53, 49, 10.1016/j.jinf.2005.10.004 · doi:10.1016/j.jinf.2005.10.004
  110. Bandyk, 1991, In Situ Replacement of Vascular Prostheses Infected by Bacterial Biofilms, J. Vasc. Surg., 13, 575, 10.1016/0741-5214(91)90339-V · doi:10.1016/0741-5214(91)90339-v
  111. Sohail, 2007, Management and Outcome of Permanent Pacemaker and Implantable Cardioverter-Defibrillator Infections, J. Am. Coll. Cardiol., 49, 1851, 10.1016/j.jacc.2007.01.072 · DOI · Paper page
  112. Moore, 1969, Transient Bacteremia. A Cause of Infection in Prosthetic Vascular Grafts, Am. J. Surg., 117, 342, 10.1016/0002-9610(69)90368-7 · doi:10.1016/0002-9610(69)90368-7
  113. Gharamti, 2018, Vascular Graft Infections: An Update, Infect. Dis. Clin. North Am., 32, 789, 10.1016/j.idc.2018.06.003 · DOI
  114. Vuong, 2004, Polysaccharide Intercellular Adhesin (PIA) Protects Staphylococcus Epidermidis against Major Components of the Human Innate Immune System, Cell. Microbiol., 6, 269, 10.1046/j.1462-5822.2004.00367.x · DOI · Paper page
  115. Leroy, 2012, Vascular Graft Infections, Curr. Opin. Infect. Dis., 25, 154, 10.1097/QCO.0b013e3283501853 · DOI
  116. Palau, 2024, Antibiotic Efficacy against Methicillin-Susceptible Staphylococcus Aureus Biofilms on Synthetic and Biological Vascular Grafts, Ann. Vasc. Surg., 108, 475, 10.1016/j.avsg.2024.05.038 · doi:10.1016/j.avsg.2024.05.038
  117. Lee, 2015, Risk of Aortic Dissection and Aortic Aneurysm in Patients Taking Oral Fluoroquinolone, JAMA Intern. Med., 175, 1839, 10.1001/jamainternmed.2015.5389 · DOI · Paper page
  118. Sixt, 2022, Long-Term Prognosis Following Vascular Graft Infection: A 10-Year Cohort Study, Open Forum Infect. Dis., 9, ofac054, 10.1093/ofid/ofac054 · DOI
  119. Bauer, 2024, Enterococcus-Related Vascular Graft Infection: A Case Series, Infect. Dis. Now, 54, 104940, 10.1016/j.idnow.2024.104940 · DOI
  120. Osada, 1999, Prophylaxis of Local Vascular Graft Infection with Levofloxacin Incorporated into Albumin-Sealed Dacron Graft (LVFX-ALB Graft), Microbiol. Immunol., 43, 317, 10.1111/j.1348-0421.1999.tb02411.x · doi:10.1111/j.1348-0421.1999.tb02411.x
  121. Baddour, 2014, Global and Regional Burden of Infective Endocarditis, 1990-2010: A Systematic Review of the Literature, Glob. Heart, 9, 131, 10.1016/j.gheart.2014.01.002 · DOI · Paper page
  122. Lauten, 2021, Bacterial Biofilms in Infective Endocarditis: An in Vitro Model to Investigate Emerging Technologies of Antimicrobial Cardiovascular Device Coatings, Clin. Res. Cardiol., 110, 323, 10.1007/s00392-020-01669-y · DOI
  123. Kouijzer, J.J.P., Noordermeer, D.J., van Leeuwen, W.J., Verkaik, N.J., and Lattwein, K.R. (2022). Native Valve, Prosthetic Valve, and Cardiac Device-Related Infective Endocarditis: A Review and Update on Current Innovative Diagnostic and Therapeutic Strategies. Front. Cell Dev. Biol., 10. · DOI
  124. Jung, 2012, Platelets Enhance Biofilm Formation and Resistance of Endocarditis-Inducing Streptococci on the Injured Heart Valve, J. Infect. Dis., 205, 1066, 10.1093/infdis/jis021 · DOI
  125. Delgado, 2023, 2023 ESC Guidelines for the Management of Endocarditis, Eur. Heart J., 44, 3948, 10.1093/eurheartj/ehad193 · DOI · Paper page
  126. Iversen, 2019, Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis, N. Engl. J. Med., 380, 415, 10.1056/NEJMoa1808312 · DOI · Paper page
  127. Bundgaard, 2019, Long-Term Outcomes of Partial Oral Treatment of Endocarditis, N. Engl. J. Med., 380, 1373, 10.1056/NEJMc1902096 · DOI
  128. Wiingaard, 2022, Five-Year Outcomes of the Partial Oral Treatment of Endocarditis (POET) Trial, N. Engl. J. Med., 386, 601, 10.1056/NEJMc2114046 · doi:10.1056/nejmc2114046
  129. Cremieux, 1989, Evaluation of Antibiotic Diffusion into Cardiac Vegetations by Quantitative Autoradiography, J. Infect. Dis., 159, 938, 10.1093/infdis/159.5.938 · DOI · Paper page
  130. McAllister, 2019, Global, Regional, and National Estimates of Pneumonia Morbidity and Mortality in Children Younger than 5 Years between 2000 and 2015: A Systematic Analysis, Lancet Glob. Health, 7, e47, 10.1016/S2214-109X(18)30408-X · DOI · Paper page
  131. Ding, 2021, Pulmonary Biofilm-Based Chronic Infections and Inhaled Treatment Strategies, Int. J. Pharm., 604, 120768, 10.1016/j.ijpharm.2021.120768 · DOI
  132. Kolpen, 2022, Bacterial Biofilms Predominate in Both Acute and Chronic Human Lung Infections, Thorax, 77, 1015, 10.1136/thoraxjnl-2021-217576 · DOI · Paper page
  133. Short, B., Williams, C., Litherland, G., Lundy, F., Mackay, W., and Ramage, G. (2020). Development and Characterisation of a Multi-Species COPD Biofilm. Eur. Respir. J., 56. · doi:10.1183/13993003.congress-2020.2053
  134. Short, 2024, Informed Development of a Multi-Species Biofilm in Chronic Obstructive Pulmonary Disease, APMIS Acta Pathol. Microbiol. Immunol. Scand., 132, 336, 10.1111/apm.13386 · DOI
  135. Ciofu, 2010, Pseudomonas Aeruginosa Biofilms in Cystic Fibrosis, Future Microbiol., 5, 1663, 10.2217/fmb.10.125 · DOI · Paper page
  136. Diaconu, 2018, Endotracheal Tube Biofilm and Its Impact on the Pathogenesis of Ventilator-Associated Pneumonia, J. Crit. Care Med. Univ. Med. Si Farm. Din Targu-Mures, 4, 50
  137. Pirrone, 2016, Microbiome, Biofilms, and Pneumonia in the ICU, Curr. Opin. Infect. Dis., 29, 160, 10.1097/QCO.0000000000000255 · DOI
  138. Inglis, 1989, Tracheal Tube Biofilm as a Source of Bacterial Colonization of the Lung, J. Clin. Microbiol., 27, 2014, 10.1128/jcm.27.9.2014-2018.1989 · DOI · Paper page
  139. Adair, 1999, Implications of Endotracheal Tube Biofilm for Ventilator-Associated Pneumonia, Intensive Care Med., 25, 1072, 10.1007/s001340051014 · DOI · Paper page
  140. Vandecandelaere, I., Matthijs, N., Van Nieuwerburgh, F., Deforce, D., Vosters, P., De Bus, L., Nelis, H.J., Depuydt, P., and Coenye, T. (2012). Assessment of Microbial Diversity in Biofilms Recovered from Endotracheal Tubes Using Culture Dependent and Independent Approaches. PLoS ONE, 7. · DOI
  141. Vandecandelaere, 2013, The Presence of Antibiotic-Resistant Nosocomial Pathogens in Endotracheal Tube Biofilms and Corresponding Surveillance Cultures, Pathog. Dis., 69, 142, 10.1111/2049-632X.12100 · DOI
  142. Pneumatikos, 2009, Ventilator-Associated Pneumonia or Endotracheal Tube-Associated Pneumonia? An Approach to the Pathogenesis and Preventive Strategies Emphasizing the Importance of Endotracheal Tube, Anesthesiology, 110, 673, 10.1097/ALN.0b013e31819868e0 · DOI · Paper page
  143. Vandecandelaere, 2015, Microbial Composition and Antibiotic Resistance of Biofilms Recovered from Endotracheal Tubes of Mechanically Ventilated Patients, Adv. Exp. Med. Biol., 830, 137, 10.1007/978-3-319-11038-7_9 · DOI
  144. Restrepo, 2013, Comparison of the Bacterial Etiology of Early-Onset and Late-Onset Ventilator-Associated Pneumonia in Subjects Enrolled in 2 Large Clinical Studies, Respir. Care, 58, 1220, 10.4187/respcare.02173 · DOI
  145. Boltey, 2017, 5 Nursing Strategies to Prevent Ventilator-Associated Pneumonia, Am. Nurse Today, 12, 42
  146. Klompas, 2022, Strategies to Prevent Ventilator-Associated Pneumonia, Ventilator-Associated Events, and Nonventilator Hospital-Acquired Pneumonia in Acute-Care Hospitals: 2022 Update, Infect. Control Hosp. Epidemiol., 43, 687, 10.1017/ice.2022.88 · DOI · Paper page
  147. Mokrani, 2023, Antibiotic Stewardship in the ICU: Time to Shift into Overdrive, Ann. Intensive Care, 13, 39, 10.1186/s13613-023-01134-9 · DOI
  148. Ture, 2023, Antimicrobial Stewardship in the Intensive Care Unit, J. Intensive Med., 3, 244, 10.1016/j.jointm.2022.10.001 · DOI
  149. Geremia, 2024, Impact of Infection Control Measures and Antibiotic Stewardship Programs on Multidrug-Resistant Klebsiella Pneumoniae Prevalence in Intensive Care Unit, Infect. Dis. Trop. Med., 10, e1413
  150. Shams, 2005, Guide to Selection of Fluoroquinolones in Patients with Lower Respiratory Tract Infections, Drugs, 65, 949, 10.2165/00003495-200565070-00004 · doi:10.2165/00003495-200565070-00004
  151. Wise, 1991, Comparative Penetration of Selected Fluoroquinolones into Respiratory Tract Fluids and Tissues, Am. J. Med., 91, 67S, 10.1016/0002-9343(91)90313-M · doi:10.1016/0002-9343(91)90313-m
  152. Usman, 2023, Synergistic Effects of Gentamicin, Cefepime, and Ciprofloxacin on Biofilm of Pseudomonas Aeruginosa, Infect. Drug Resist., 16, 5887, 10.2147/IDR.S426111 · DOI
  153. Han, J., Luo, J., Du, Z., Chen, Y., and Liu, T. (2023). Synergistic Effects of Baicalin and Levofloxacin Against Hypervirulent Klebsiella Pneumoniae Biofilm In Vitro. Curr. Microbiol., 80. · DOI
  154. Vandevelde, 2014, Antibiotic Activity against Naive and Induced Streptococcus Pneumoniae Biofilms in an in Vitro Pharmacodynamic Model, Antimicrob. Agents Chemother., 58, 1348, 10.1128/AAC.01858-13 · doi:10.1128/aac.01858-13
  155. Tamma, P.D., Heil, E.L., Justo, J.A., Mathers, A.J., Satlin, M.J., and Bonomo, R.A. (2024). Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections. Clin. Infect. Dis., ciae403. · DOI · Paper page
  156. Craddock, V.D., Steere, E.L., Harman, H., and Britt, N.S. (2023). Activity of Delafloxacin and Comparator Fluoroquinolones against Multidrug-Resistant Pseudomonas Aeruginosa in an In Vitro Cystic Fibrosis Sputum Model. Antibiotics, 12. · DOI
  157. Millar, 2021, Delafloxacin--A Novel Fluoroquinolone for the Treatment of Ciprofloxacin-Resistant Pseudomonas Aeruginosa in Patients with Cystic Fibrosis, Clin. Respir. J., 15, 116, 10.1111/crj.13262 · DOI
  158. Kocsis, 2017, New Treatment Options for Lower Respiratory Tract Infections, Expert Opin. Pharmacother., 18, 1345, 10.1080/14656566.2017.1363179 · DOI
  159. Bauer, 2013, A Combined Pharmacodynamic Quantitative and Qualitative Model Reveals the Potent Activity of Daptomycin and Delafloxacin against Staphylococcus Aureus Biofilms, Antimicrob. Agents Chemother., 57, 2726, 10.1128/AAC.00181-13 · DOI
  160. Siala, 2014, Comparison of the Antibiotic Activities of Daptomycin, Vancomycin, and the Investigational Fluoroquinolone Delafloxacin against Biofilms from Staphylococcus Aureus Clinical Isolates, Antimicrob. Agents Chemother., 58, 6385, 10.1128/AAC.03482-14 · DOI
  161. Kara, A., Massaro, C., Giammanco, G.M., Alduina, R., and Boussoualim, N. (2024). Phylogenetic Diversity, Antibiotic Resistance, and Virulence of Escherichia Coli Strains from Urinary Tract Infections in Algeria. Antibiotics, 13. · DOI
  162. David, A., Tahrioui, A., Tareau, A.-S., Forge, A., Gonzalez, M., Bouffartigues, E., Lesouhaitier, O., and Chevalier, S. (2024). Pseudomonas Aeruginosa Biofilm Lifecycle: Involvement of Mechanical Constraints and Timeline of Matrix Production. Antibiotics, 13. · DOI
  163. Chakrabarty, 2022, Targeting Microbial Bio-Film: An Update on MDR Gram-Negative Bio-Film Producers Causing Catheter-Associated Urinary Tract Infections, Appl. Biochem. Biotechnol., 194, 2796, 10.1007/s12010-021-03711-9 · DOI
  164. Ronald, 2002, The Etiology of Urinary Tract Infection: Traditional and Emerging Pathogens, Am. J. Med., 113, 14, 10.1016/S0002-9343(02)01055-0 · DOI · Paper page
  165. Nielsen, D.W., Klimavicz, J.S., Cavender, T., Wannemuehler, Y., Barbieri, N.L., Nolan, L.K., and Logue, C.M. (2018). The Impact of Media, Phylogenetic Classification, and E. Coli Pathotypes on Biofilm Formation in Extraintestinal and Commensal E. Coli From Humans and Animals. Front. Microbiol., 9. · DOI
  166. Mirzahosseini, 2023, Correlation of Biofilm Formation, Virulence Factors, and Phylogenetic Groups among Escherichia Coli Strains Causing Urinary Tract Infection: A Global Systematic Review and Meta-Analysis, J. Res. Med. Sci., 28, 66
  167. Wang, 2013, Bacterial Characteristics and Glycemic Control in Diabetic Patients with Escherichia Coli Urinary Tract Infection, J. Microbiol. Immunol. Infect. Wei Mian Yu Gan Ran Za Zhi, 46, 24, 10.1016/j.jmii.2011.12.024 · DOI
  168. Mittal, 2015, Biofilm and Multidrug Resistance in Uropathogenic Escherichia Coli, Pathog. Glob. Health, 109, 26, 10.1179/2047773215Y.0000000001 · doi:10.1179/2047773215y.0000000001
  169. Egbule, 2024, Assessment of Biofilm Forming Capability and Antibiotic Resistance in Proteus Mirabilis Colonizing Indwelling Catheter, Pak. J. Biol. Sci. PJBS, 27, 268, 10.3923/pjbs.2024.268.275 · doi:10.3923/pjbs.2024.268.275
  170. Jacobsen, 2011, Proteus Mirabilis Biofilms and Catheter-Associated Urinary Tract Infections, Virulence, 2, 460, 10.4161/viru.2.5.17783 · DOI · Paper page
  171. Li, L., Gao, X., Li, M., Liu, Y., Ma, J., Wang, X., Yu, Z., Cheng, W., Zhang, W., and Sun, H. (2024). Relationship between Biofilm Formation and Antibiotic Resistance of Klebsiella Pneumoniae and Updates on Antibiofilm Therapeutic Strategies. Front. Cell. Infect. Microbiol., 14. · DOI
  172. Rastegar, 2023, Quinolone Resistance and Biofilm Formation Capability of Uropathogenic Escherichia Coli Isolates from an Iranian Inpatients’ Population, Mol. Biol. Rep., 50, 8073, 10.1007/s11033-023-08704-x · doi:10.1007/s11033-023-08704-x
  173. Giovagnorio, F., De Vito, A., Madeddu, G., Parisi, S.G., and Geremia, N. (2023). Resistance in Pseudomonas Aeruginosa: A Narrative Review of Antibiogram Interpretation and Emerging Treatments. Antibiotics, 12. · DOI
  174. Aniba, R., Dihmane, A., Raqraq, H., Ressmi, A., Nayme, K., Timinouni, M., and Barguigua, A. (2024). Molecular and Phenotypic Characterization of Biofilm Formation and Antimicrobial Resistance Patterns of Uropathogenic Staphylococcus Haemolyticus Isolates in Casablanca, Morocco. Diagn. Microbiol. Infect. Dis., 110. · doi:10.1016/j.diagmicrobio.2024.116483
  175. Raya, S., Belbase, A., Dhakal, L., Govinda Prajapati, K., Baidya, R., and Kishor Bimali, N. (2019). In-Vitro Biofilm Formation and Antimicrobial Resistance of Escherichia Coli in Diabetic and Nondiabetic Patients. BioMed Res. Int., 2019. · DOI
  176. Colpan, 2013, Escherichia Coli Sequence Type 131 (ST131) Subclone H30 as an Emergent Multidrug-Resistant Pathogen among US Veterans, Clin. Infect. Dis., 57, 1256, 10.1093/cid/cit503 · DOI · Paper page
  177. Elhosseini, M.A., El-Banna, T.E., Sonbol, F.I., and El-Bouseary, M.M. (2024). Potential Antivirulence Activity of Sub-Inhibitory Concentrations of Ciprofloxacin against Proteus Mirabilis Isolates: An in-Vitro and in-Vivo Study. Ann. Clin. Microbiol. Antimicrob., 23. · DOI
  178. Wasfi, 2012, Antimicrobial Activities against Biofilm Formed by Proteus Mirabilis Isolates from Wound and Urinary Tract Infections, Indian J. Med. Microbiol., 30, 76, 10.4103/0255-0857.93044 · doi:10.4103/0255-0857.93044
  179. Whelan, S., O’Grady, M.C., Corcoran, G.D., Finn, K., and Lucey, B. (2022). Effect of Sub-Inhibitory Concentrations of Nitrofurantoin, Ciprofloxacin, and Trimethoprim on In Vitro Biofilm Formation in Uropathogenic Escherichia Coli (UPEC). Med. Sci., 11. · DOI
  180. Robino, 2017, Effect of Different Antibiotics on Biofilm Produced by Uropathogenic Escherichia Coli Isolated from Children with Urinary Tract Infection, Pathog. Dis., 75, ftx053
  181. Rafaque, 2020, In-Vitro Investigation of Antibiotics Efficacy Against Uropathogenic Escherichia Coli Biofilms and Antibiotic Induced Biofilm Formation at Sub-Minimum Inhibitory Concentration of Ciprofloxacin, Infect. Drug Resist., 13, 2801, 10.2147/IDR.S258355 · doi:10.2147/idr.s258355
  182. Slade-Vitković, M., Batarilo, I., Bielen, L., Maravić-Vlahoviček, G., and Bedenić, B. (2024). In Vitro Antibiofilm Activity of Fosfomycin Alone and in Combination with Other Antibiotics against Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas Aeruginosa. Pharmaceuticals, 17. · DOI
  183. Saini, 2015, Azithromycin and Ciprofloxacin: A Possible Synergistic Combination against Pseudomonas Aeruginosa Biofilm-Associated Urinary Tract Infections, Int. J. Antimicrob. Agents, 45, 359, 10.1016/j.ijantimicag.2014.11.008 · doi:10.1016/j.ijantimicag.2014.11.008
  184. Wang, 2024, The Potentiation Activity of Azithromycin in Combination with Colistin or Levofloxacin Against Pseudomonas Aeruginosa Biofilm Infection, Infect. Drug Resist., 17, 1259, 10.2147/IDR.S438576 · DOI
  185. Zeng, B., Li, Y., Khan, N., Su, A., Yang, Y., Mi, P., Jiang, B., Liang, Y., and Duan, L. (2024). Yin-Yang: Two Sides of Extracellular Vesicles in Inflammatory Diseases. J. Nanobiotechnol., 22. · DOI
  186. Kanwal, 2022, Synthesis and Characterization of Carbon Dots Coated CaCO3 Nanocarrier for Levofloxacin Against Multidrug Resistance Extended-Spectrum Beta-Lactamase Escherichia Coli of Urinary Tract Infection Origin, Microb. Drug Resist. Larchmt. N, 28, 106, 10.1089/mdr.2020.0621 · doi:10.1089/mdr.2020.0621
  187. Pekmezovic, 2019, Host–Pathogen Interactions during Female Genital Tract Infections, Trends Microbiol., 27, 982, 10.1016/j.tim.2019.07.006 · DOI
  188. Pan, J., Singh, A., Hanning, K., Hicks, J., and Williamson, A. (2024). A Role for the ATP-Dependent DNA Ligase Lig E of Neisseria Gonorrhoeae in Biofilm Formation. BMC Microbiol., 24. · DOI · Paper page
  189. Goldstein, 2024, Impact of Molecular Ciprofloxacin Resistance Testing in Management of Gonorrhoea in a Large Urban Clinic, Sex. Transm. Infect., 100, 226, 10.1136/sextrans-2023-056099 · doi:10.1136/sextrans-2023-056099
  190. Collins, 2024, Target-Mediated Fluoroquinolone Resistance in Neisseria Gonorrhoeae: Actions of Ciprofloxacin against Gyrase and Topoisomerase IV, ACS Infect. Dis., 10, 1351, 10.1021/acsinfecdis.4c00041 · DOI
  191. Kagawa, 2024, Molecular Epidemiological and Antimicrobial-Resistant Mechanisms Analysis of Prolonged Neisseria Gonorrhoeae Collection between 1971 and 2005 in Japan, JAC-Antimicrob. Resist., 6, dlae040, 10.1093/jacamr/dlae040 · DOI
  192. Yueyue, 2022, Pathogenicity and Virulence of Mycoplasma Genitalium: Unraveling Ariadne’s Thread, Virulence, 13, 1161, 10.1080/21505594.2022.2095741 · DOI
  193. Evsyutina, D.V., Semashko, T.A., Galyamina, M.A., Kovalchuk, S.I., Ziganshin, R.H., Ladygina, V.G., Fisunov, G.Y., and Pobeguts, O.V. (2022). Molecular Basis of the Slow Growth of Mycoplasma Hominis on Different Energy Sources. Front. Cell. Infect. Microbiol., 12. · doi:10.3389/fcimb.2022.918557
  194. Hackett, A., Yossepowitch, O., Goor, Y., Sheffer, R., Schwartz, O., Sheftel, Y., Weiss, Y., and Maor, Y. (2024). Prevalence and Risk Factors for Antimicrobial Resistance of Mycoplasma Genitalium Infections in a High-Risk Population. J. Clin. Med., 13. · DOI
  195. Ertl, 2024, Concurrent parC and gyrA Fluoroquinolone Resistance Mutations and Associated Strains in Mycoplasma Genitalium in Queensland, Australia, J. Antimicrob. Chemother., 79, 467, 10.1093/jac/dkad373 · DOI
  196. Rowlands, 2021, A Requirement for Flow to Enable the Development of Ureaplasma Parvum Biofilms in Vitro, J. Appl. Microbiol., 131, 2579, 10.1111/jam.15120 · DOI
  197. Wu, 2024, Trends of Fluoroquinolones Resistance in Mycoplasma and Ureaplasma Urogenital Isolates: Systematic Review and Meta-Analysis, J. Glob. Antimicrob. Resist., 36, 13, 10.1016/j.jgar.2023.11.007 · DOI
  198. Garcia, 2024, Phase Variable Colony Variants Are Conserved across Gardnerella Spp. and Exhibit Different Virulence-Associated Phenotypes, mSphere, 9, e0045024, 10.1128/msphere.00450-24 · DOI
  199. Swidsinski, 2011, Response of Gardnerella Vaginalis Biofilm to 5 Days of Moxifloxacin Treatment, FEMS Immunol. Med. Microbiol., 61, 41, 10.1111/j.1574-695X.2010.00743.x · DOI
  200. Esposito, 2017, Diagnosis and Management of Skin and Soft-Tissue Infections (SSTI). A Literature Review and Consensus Statement: An Update, J. Chemother. Florence Italy, 29, 197, 10.1080/1120009X.2017.1311398 · DOI

200 of 233 shown

Cited by

Metadata

Authors
Geremia, N., Giovagnorio, F., Colpani, A., De Vito, A., Botan, A., Stroffolini, G., Toc, D.-A., Zerbato, V., Principe, L., Madeddu, G., Luzzati, R., Parisi, S. G., & Di Bella, S.
Venue
Pharmaceuticals
Publisher
MDPI AG
Published
2024-12-11
Volume
17
Issue
12
Pages
1673
ISSN
1424-8247
Cited by
42
References
4
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.